The National Heart, Lung, and Blood Institute (NHLBI) awarded a $543,268 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to the Beckman Research Institute of the City of Hope to conduct research on RNA-mediated endotheliopathy and diabetic vasculopathy. The research aims to identify the roles and mechanisms of long non-coding RNAs in driving endothelial dysfunction, determine the impact of RNA epitranscriptional modifications in diabetic endotheliopathy, and evaluate the efficacy of nanoparticle-mediated epigenetic therapeutics for diabetic peripheral artery disease. The project will leverage expertise in RNA biology, chromatin regulation, endothelial cell function, gene therapy, and nanomedicine. Through sub-awards, Arizona State University will develop nanoparticle therapeutics targeting endothelial pathologies, and the Methodist Hospital Research Institute will consult on the design and synthesis of modified RNAs to enhance vascular regeneration. The award period is from Jul 1, 2024 to Jun 30, 2031.
Generated 2/25/25, 2:49 AM